Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes - Full Text View

Sponsor:	Yonsei University
Information provided by:	Yonsei University
ClinicalTrials.gov Identifier:	NCT00598013

Purpose

The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.

Condition	Intervention
Kidney Transplantation Insulin Resistance Atherosclerosis	Drug: Pioglitazone

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

MedlinePlus related topics: Atherosclerosis Diabetes Medicines Kidney Transplantation

Drug Information available for: Insulin Insulin beef Pioglitazone Pioglitazone hydrochloride

U.S. FDA Resources

Further study details as provided by Yonsei University:

Primary Outcome Measures:

Insulin Resistance and Insulin Secretion [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

carotid intima-media thickness [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment:	83
Study Start Date:	November 2004
Study Completion Date:	November 2007
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: Pioglitazone The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
No Intervention: 2

Detailed Description:

This is a prospective, randomized, open-label study. The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.

After treatment, we estimated insulin sensitivity index for transplantation,first phase and second phase insulin secretion, secretion area under the curve,and carotid intima-media thickness.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Renal allograft recipients were eligible to participate in the study if they were aged ≥ 18 years, had no previous history of organ transplantation and were not currently using steroids or other immunosuppressants.

Exclusion Criteria:

Diabetes before transplantation
Severe metabolic or infectious disease
Hepatic disease
Congestive heart failure (New York Heart Association II-IV)
Cadaver donor kidney donor transplantation
Unstable condition of the transplanted kidney

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00598013

Locations

Korea, Republic of
Yonsei University College of Medicine
Seoul, Korea, Republic of, 120-752

Sponsors and Collaborators

Yonsei University

Investigators

Principal Investigator:

Hyun Chul Lee, Doctor

Yonsei University College of Medicine

More Information

No publications provided by Yonsei University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Han SJ, Hur KY, Kim YS, Kang ES, Kim SI, Kim MS, Kwak JY, Kim DJ, Choi SH, Cha BS, Lee HC. Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. Nephrol Dial Transplant. 2010 Mar;25(3):976-84. Epub 2009 Oct 28.

Responsible Party:	Hyun Chul Lee, Professor, Department of internal medicine, Yonsei University College of Medicine
ClinicalTrials.gov Identifier:	NCT00598013 History of Changes
Other Study ID Numbers:	4-2004-0082, 82-2-2228-1930
Study First Received:	January 9, 2008
Last Updated:	January 17, 2008
Health Authority:	Korea: Food and Drug Administration

Keywords provided by Yonsei University:

Kidney Transplantation
Thiazolidinediones
Insulin Resistance
Atherosclerosis

Additional relevant MeSH terms:

Atherosclerosis
Insulin Resistance
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Hyperinsulinism

Glucose Metabolism Disorders
Metabolic Diseases
Pioglitazone
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012